• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

NxThera Inc.

3M names CEO Roman as board chair | Personnel Moves – February 7, 2019

February 7, 2019 By Fink Densford

3M (NYSE:MMM) said yesterday that its board of directors nominated CEO Mike Roman as its new chairperson, with current exec chair Inge Thulin announcing their intention to retire. The move is slated to take effect following the St. Paul, Minn.-based company’s annual meeting of shareholders on May 14. “Under Inge’s leadership, 3M evolved into a more […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: 3m, AdvaMed, Amazon, Biospace Med, Boston Scientific, Digirad Corp., excelmedical, Medtronic, Misonix, Myomo Inc, NxThera Inc., Presbia, Repro-Med Systems Inc., SPR Therapeutics, venturemed

NxThera spinout NxPhase lands $10m for vapor ablation tech

December 3, 2018 By Chris Newmarker

NxPhase Medical – spun out of NxThera when Boston Scientific bought it this year– has raised more than $10 million, according to a recent U.S. Securities and Exchange Commission filing. Maple Grove, Minn.–based NxPhase is focused on using convective thermal water vapor to treat prostate, kidney, and bladder cancer, according to its LinkedIn page. Get the […]

Filed Under: Business/Financial News, News Well, Surgical Tagged With: nxphasemedical, NxThera Inc.

Boston Scientific closes $400m NxThera buy

April 30, 2018 By Brad Perriello

Boston Scientific (NYSE:BSX) said today that it closed the $406 million acquisition of NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal called for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led […]

Filed Under: Mergers & Acquisitions, Urology, Wall Street Beat Tagged With: Boston Scientific, NxThera Inc.

UPDATE: Boston Scientific lays out $406m for NxThera which plans spin-out of cancer treatment tech

March 21, 2018 By Brad Perriello

Updated with comments from NxThera president & CEO Bob Paulson. Boston Scientific (NYSE:BSX) said today that it laid out a $406 million deal for NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal calls for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in […]

Filed Under: Mergers & Acquisitions, Urology, Wall Street Beat Tagged With: Boston Scientific, NxThera Inc.

NxThera touts 3-year Rezūm trial results

January 4, 2018 By Fink Densford

NxThera today released three-year results from a trial of its Rezūm convective water vapor wave energy system, touting effective and durable relief from lower urinary tract symptoms for patients with benign prostatic hyperplasia. The trial was co-authored by co-principal investigators Dr. Kevin McVary of Southern Illinois University School of Medicine and Dr. Claus Roehrborn of the […]

Filed Under: Clinical Trials, Urology Tagged With: NxThera Inc.

NxThera adds $6m for Rezūm prostate device

July 21, 2017 By Brad Perriello

NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise […]

Filed Under: Funding Roundup, Urology, Wall Street Beat Tagged With: NxThera Inc.

7 medtech stories we missed this week: May 19, 2017

May 19, 2017 By Danielle Kirsh

From FDA clearances to touting study data, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. XpandOrtho wins FDA 510(k) clearance XpandOrtho announced in a May 17 press release that it has received FDA 510(k) clearance for its electronic soft tissue balancing instrument for total knee replacement surgery. […]

Filed Under: 510(k), Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: Body Vision Medical, Exactech Inc., lombardmedical, MedTech, NxThera Inc., Rivanna Medical, Visionsense, XpandOrtho

NxThera touts reimbursement win with Humana, Aetna

April 6, 2017 By Fink Densford

NxThera said today that health insurers Humana and Aetna will now provide coverage for its Rezūm system designed for the minimally invasive treatment of benign prostatic hyperplasia, or enlarged prostate. NxThera’s Rezūm system is designed to use radiofrequency current to create thermal energy to ablate obstructive prostate tissue which causes BPH through targeted treatments. The Maple […]

Filed Under: Business/Financial News, Urology Tagged With: NxThera Inc.

NxThera raises $15 million

March 3, 2017 By Fink Densford

NxThera  has raised $14.6 million in a new round of debt financing, according to an SEC filing posted this week. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the 1st sale noted on Jan. 13. NxThera is looking to […]

Filed Under: Business/Financial News Tagged With: NxThera Inc.

NxThera raises $12.2m

February 3, 2017 By Fink Densford

NxThera raised $12.2 million in a new round of financing, according to an SEC filing posted this week. Funds in the round come through the offering of debt, warrants, convertible promissory notes and Series C preferred stock warrants, according to the filing. Funds in the round were raised by 28 unnamed US purchasers, according to the SEC […]

Filed Under: Business/Financial News Tagged With: NxThera Inc.

Boston Scientific leads $40m round for NxThera

December 3, 2015 By Brad Perriello

NxThera said today that Boston Scientific (NYSE:BSX) led a $40 million funding round for its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Existing backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, Maple Grove, Minn.-based NxThera said. The company said it also expanded a […]

Filed Under: Funding Roundup, Urology, Wall Street Beat Tagged With: Boston Scientific, NxThera Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS